L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's Disease

被引:40
|
作者
Guridi, Jorge [1 ]
Obeso, Jose A. [1 ,2 ]
Rodriguez-Oroz, Maria C. [1 ,2 ]
Lozano, Andres A. [3 ]
Manrique, Miguel [1 ]
机构
[1] Univ Navarra, Dept Neurosci, Div Neurosurg, Univ Clin, Pamplona 31008, Spain
[2] Univ Navarra, Ctr Neurosci, Pamplona 31008, Spain
[3] Univ Toronto, Toronto Western Hosp, Div Neurosurg, Toronto, ON M5T 2S8, Canada
关键词
deep brain stimulation; L-dopa-induced dyskinesia; pallidotomy; Parkinson's disease; subthalamic nucleus; subthalamotomy; thalamotomy;
D O I
10.1227/01.neu.0000315998.58022.55
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE: To assess the impact of different surgical targets and techniques, such as ablation and deep brain stimulation, to treat patients with L-dopa-induced dyskinesia (LID), a major therapeutic complication of Parkinson's disease. METHODS: This review analyzes the effects of early surgical procedures to treat hyperkinesia and the current methods and targets used to combat LID in Parkinson's disease, which are mainly thalamotomy, pallidotomy, and deep brain stimulation of the globus pallidus internus and the subthalamic nucleus. RESULTS: Available information indicates that surgery of the globus pallidus internus and thalamus (the pallidal receiving area) and of the subthalamic nucleus has a pronounced antidyskinetic effect. This effect is associated with a concomitant improvement in the parkinsonian ("off"-medication) state. Although it is more profound with pallidal and subthalamic surgery, such an effect can also be observed to some extent with thalamic surgery. The latter is attributable to the fact that surgery of the ventralis intermedius is primarily effective for treating tremor. An integral pallidothalamic pathway is needed for dyskinesia to be expressed. Thus, LID is less frequent after subthalamotomy or deep brain stimulation of the subthalamic nucleus through a functional effect mediated by the physiological normalization of the motor system and by an indirect effect associated with a reduction in the daily dose Of L-dopa. CONCLUSION: Surgery is the only treatment available for Parkinson's disease that can predictably improve both the parkinsonian motor syndrome and LID. The exact mechanisms involved in these effects are not well understood. Pallidal and thalamic surgery affecting pallidal relays reduce LID frequency by disrupting the pallidothalamic circuit, probably eliminating the neuronal activity associated with dyskinesia. Alternatively, the antidyskinetic effect of subthalamic nucleus surgery may in part be attributable to a reduction in the L-dopa dose as well as to the stabilization of the basal ganglia circuits after the surgical procedure.
引用
收藏
页码:311 / 323
页数:13
相关论文
共 50 条
  • [1] The Pharmacology of L-DOPA-Induced Dyskinesia in Parkinson's Disease
    Huot, Philippe
    Johnston, Tom H.
    Koprich, James B.
    Fox, Susan H.
    Brotchie, Jonathan M.
    PHARMACOLOGICAL REVIEWS, 2013, 65 (01) : 171 - 222
  • [2] Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease
    Corsi, Sara
    Scheggi, Simona
    Pardu, Alessandra
    Braccagni, Giulia
    Caruso, Donatella
    Cioffi, Lucia
    Diviccaro, Silvia
    Gentile, Mauro
    Fanni, Silvia
    Stancampiano, Roberto
    Gambarana, Carla
    Melcangi, Roberto Cosimo
    Frau, Roberto
    Carta, Manolo
    EXPERIMENTAL NEUROLOGY, 2023, 363
  • [3] Animal Models of L-Dopa-Induced Dyskinesia in Parkinson's Disease
    Cenci, M. Angela
    Crossman, Alan R.
    MOVEMENT DISORDERS, 2018, 33 (06) : 889 - 899
  • [4] Receptor Heteromers in Parkinson's Disease and L-DOPA-Induced Dyskinesia
    Fiorentini, Chiara
    Savoia, Paola
    Savoldi, Daria
    Missale, Cristina
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2013, 12 (08) : 1101 - 1113
  • [5] Nalbuphine Efficacy for L-Dopa-induced Dyskinesia in Parkinson Disease
    Mouradian, M. Maral
    Papa, Stella M.
    Voronkov, Michael
    Braithwaite, Steven P.
    NEUROTHERAPEUTICS, 2016, 13 (03) : 650 - 650
  • [6] Repurposing drugs to treat L-DOPA-induced dyskinesia in Parkinson's disease
    Johnston, Tom H.
    Lacoste, Alix M. B.
    Visanji, Naomi P.
    Lang, Anthony E.
    Fox, Susan H.
    Brotchie, Jonathan M.
    NEUROPHARMACOLOGY, 2019, 147 : 11 - 27
  • [7] mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia
    Sebastianutto, Irene
    Cenci, Maria Angela
    CURRENT OPINION IN PHARMACOLOGY, 2018, 38 : 81 - 89
  • [8] L-dopa-induced dyskinesia in Parkinson's disease: The French dopamip survey
    Rascol, O.
    Negre-Pages, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 205 - 205
  • [9] Abnormal cortical facilitation and L-dopa-induced dyskinesia in Parkinson's disease
    Guerra, Andrea
    Suppa, Antonio
    D'Onofrio, Valentina
    Di Stasio, Flavio
    Asci, Francesco
    Fabbrini, Giovanni
    Berardelli, Alfredo
    BRAIN STIMULATION, 2019, 12 (06) : 1517 - 1525
  • [10] μ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease
    Bezard, Erwan
    Li, Qin
    Hulme, Heather
    Fridjonsdottir, Elva
    Nilsson, Anna
    Pioli, Elsa
    Andren, Per E.
    Crossman, Alan R.
    JOURNAL OF NEUROSCIENCE, 2020, 40 (35): : 6812 - 6819